Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis.

Smeester BA, Slipek NJ, Pomeroy EJ, Bomberger HE, Shamsan GA, Peterson JJ, Crosby MR, Draper GM, Becklin KL, Rahrmann EP, McCarthy JB, Odde DJ, Wood DK, Largaespada DA, Moriarity BS.

Oncogene. 2019 Oct 3. doi: 10.1038/s41388-019-1041-x. [Epub ahead of print]

PMID:
31582836
2.

Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis.

Huang M, Tailor J, Zhen Q, Gillmor AH, Miller ML, Weishaupt H, Chen J, Zheng T, Nash EK, McHenry LK, An Z, Ye F, Takashima Y, Clarke J, Ayetey H, Cavalli FMG, Luu B, Moriarity BS, Ilkhanizadeh S, Chavez L, Yu C, Kurian KM, Magnaldo T, Sevenet N, Koch P, Pollard SM, Dirks P, Snyder MP, Largaespada DA, Cho YJ, Phillips JJ, Swartling FJ, Morrissy AS, Kool M, Pfister SM, Taylor MD, Smith A, Weiss WA.

Cell Stem Cell. 2019 Sep 5;25(3):433-446.e7. doi: 10.1016/j.stem.2019.05.013. Epub 2019 Jun 13.

3.

EditR: A Method to Quantify Base Editing from Sanger Sequencing.

Kluesner MG, Nedveck DA, Lahr WS, Garbe JR, Abrahante JE, Webber BR, Moriarity BS.

CRISPR J. 2018 Jun;1:239-250. doi: 10.1089/crispr.2018.0014.

4.

HBx-K130M/V131I Promotes Liver Cancer in Transgenic Mice via AKT/FOXO1 Signaling Pathway and Arachidonic Acid Metabolism.

Chiu AP, Tschida BR, Sham TT, Lo LH, Moriarity BS, Li XX, Lo RC, Hinton DE, Rowlands DK, Chan CO, Mok DKW, Largaespada DA, Warner N, Keng VW.

Mol Cancer Res. 2019 Jul;17(7):1582-1593. doi: 10.1158/1541-7786.MCR-18-1127. Epub 2019 Apr 11.

PMID:
30975706
5.

Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas.

Rathe SK, Popescu FE, Johnson JE, Watson AL, Marko TA, Moriarity BS, Ohlfest JR, Largaespada DA.

Sci Rep. 2019 Jan 23;9(1):358. doi: 10.1038/s41598-018-36840-z.

6.

Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors.

Beckmann PJ, Larson JD, Larsson AT, Ostergaard JP, Wagner S, Rahrmann EP, Shamsan GA, Otto GM, Williams RL, Wang J, Lee C, Tschida BR, Das P, Dubuc AM, Moriarity BS, Picard D, Wu X, Rodriguez FJ, Rosemarie Q, Krebs RD, Molan AM, Demer AM, Frees MM, Rizzardi AE, Schmechel SC, Eberhart CG, Jenkins RB, Wechsler-Reya RJ, Odde DJ, Huang A, Taylor MD, Sarver AL, Largaespada DA.

Cancer Res. 2019 Mar 1;79(5):905-917. doi: 10.1158/0008-5472.CAN-18-1261. Epub 2019 Jan 23.

PMID:
30674530
7.

Cancer Gene Discovery Utilizing Sleeping Beauty Transposon Mutagenesis.

Becklin KL, Smeester BA, Moriarity BS.

Methods Mol Biol. 2019;1907:161-170. doi: 10.1007/978-1-4939-8967-6_13.

PMID:
30542999
8.

Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-cell Lymphoma.

Rahrmann EP, Wolf NK, Otto GM, Heltemes-Harris L, Ramsey LB, Shu J, LaRue RS, Linden MA, Rathe SK, Starr TK, Farrar MA, Moriarity BS, Largaespada DA.

Mol Cancer Res. 2019 Feb;17(2):567-582. doi: 10.1158/1541-7786.MCR-18-0582. Epub 2018 Oct 24.

PMID:
30355676
9.

Highly multiplexed genome engineering using CRISPR/Cas9 gRNA arrays.

Kurata M, Wolf NK, Lahr WS, Weg MT, Kluesner MG, Lee S, Hui K, Shiraiwa M, Webber BR, Moriarity BS.

PLoS One. 2018 Sep 17;13(9):e0198714. doi: 10.1371/journal.pone.0198714. eCollection 2018.

10.

The Molecular Imaging of Natural Killer Cells.

Shapovalova M, Pyper SR, Moriarity BS, LeBeau AM.

Mol Imaging. 2018 Jan-Dec;17:1536012118794816. doi: 10.1177/1536012118794816. Review.

11.

Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease.

Johnson MJ, Laoharawee K, Lahr WS, Webber BR, Moriarity BS.

Sci Rep. 2018 Aug 14;8(1):12144. doi: 10.1038/s41598-018-30358-0.

12.

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.

Li Y, Hermanson DL, Moriarity BS, Kaufman DS.

Cell Stem Cell. 2018 Aug 2;23(2):181-192.e5. doi: 10.1016/j.stem.2018.06.002. Epub 2018 Jun 28.

13.

CRISPR/Cas9 library screening for drug target discovery.

Kurata M, Yamamoto K, Moriarity BS, Kitagawa M, Largaespada DA.

J Hum Genet. 2018 Feb;63(2):179-186. doi: 10.1038/s10038-017-0376-9. Epub 2017 Nov 20. Review.

PMID:
29158600
14.

Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma.

Scott MC, Temiz NA, Sarver AE, LaRue RS, Rathe SK, Varshney J, Wolf NK, Moriarity BS, O'Brien TD, Spector LG, Largaespada DA, Modiano JF, Subramanian S, Sarver AL.

Cancer Res. 2018 Jan 15;78(2):326-337. doi: 10.1158/0008-5472.CAN-17-0576. Epub 2017 Oct 24.

15.

Rapid generation of Col7a1-/- mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells.

Webber BR, O'Connor KT, McElmurry RT, Durgin EN, Eide CR, Lees CJ, Riddle MJ, Mathews WE, Frank NY, Kluth MA, Ganss C, Moriarity BS, Frank MH, Osborn MJ, Tolar J.

Lab Invest. 2017 Oct;97(10):1218-1224. doi: 10.1038/labinvest.2017.85. Epub 2017 Sep 11.

16.

Prosurvival long noncoding RNA PINCR regulates a subset of p53 targets in human colorectal cancer cells by binding to Matrin 3.

Chaudhary R, Gryder B, Woods WS, Subramanian M, Jones MF, Li XL, Jenkins LM, Shabalina SA, Mo M, Dasso M, Yang Y, Wakefield LM, Zhu Y, Frier SM, Moriarity BS, Prasanth KV, Perez-Pinera P, Lal A.

Elife. 2017 Jun 5;6. pii: e23244. doi: 10.7554/eLife.23244.

17.

CRISPR/Cas9 Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism.

Dorr CR, Remmel RP, Muthusamy A, Fisher J, Moriarity BS, Yasuda K, Wu B, Guan W, Schuetz EG, Oetting WS, Jacobson PA, Israni AK.

Drug Metab Dispos. 2017 Aug;45(8):957-965. doi: 10.1124/dmd.117.076307. Epub 2017 May 22.

18.

Relative importance of βcyto- and γcyto-actin in primary mouse embryonic fibroblasts.

Patrinostro X, O'Rourke AR, Chamberlain CM, Moriarity BS, Perrin BJ, Ervasti JM.

Mol Biol Cell. 2017 Mar 15;28(6):771-782. doi: 10.1091/mbc.E16-07-0503. Epub 2017 Jan 11.

19.

Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.

Pomeroy EJ, Lee LA, Lee RDW, Schirm DK, Temiz NA, Ma J, Gruber TA, Diaz-Flores E, Moriarity BS, Downing JR, Shannon KM, Largaespada DA, Eckfeldt CE.

Oncogene. 2017 Jun 8;36(23):3263-3273. doi: 10.1038/onc.2016.471. Epub 2016 Dec 19.

20.

Slit-Robo GTPase-Activating Protein 2 as a metastasis suppressor in osteosarcoma.

Marko TA, Shamsan GA, Edwards EN, Hazelton PE, Rathe SK, Cornax I, Overn PR, Varshney J, Diessner BJ, Moriarity BS, O'Sullivan MG, Odde DJ, Largaespada DA.

Sci Rep. 2016 Dec 14;6:39059. doi: 10.1038/srep39059.

21.

Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.

Kurata M, Rathe SK, Bailey NJ, Aumann NK, Jones JM, Veldhuijzen GW, Moriarity BS, Largaespada DA.

Sci Rep. 2016 Nov 3;6:36199. doi: 10.1038/srep36199.

22.

RALB provides critical survival signals downstream of Ras in acute myeloid leukemia.

Eckfeldt CE, Pomeroy EJ, Lee RD, Hazen KS, Lee LA, Moriarity BS, Largaespada DA.

Oncotarget. 2016 Oct 4;7(40):65147-65156. doi: 10.18632/oncotarget.11431.

23.

mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress.

Yun YS, Kim KH, Tschida B, Sachs Z, Noble-Orcutt KE, Moriarity BS, Ai T, Ding R, Williams J, Chen L, Largaespada D, Kim DH.

Mol Cell. 2016 Feb 18;61(4):625-639. doi: 10.1016/j.molcel.2016.01.013. Epub 2016 Feb 11.

24.

A novel role for SALL4 during scar-free wound healing in axolotl.

Erickson JR, Gearhart MD, Honson DD, Reid TA, Gardner MK, Moriarity BS, Echeverri K.

NPJ Regen Med. 2016;1. pii: 16016. doi: 10.1038/npjregenmed.2016.16. Epub 2016 Dec 8.

25.

Coping with cancer genes altered by copy number.

Wolf NK, Largaespada DA, Moriarity BS.

Oncotarget. 2015 Nov 3;6(34):35155-6. doi: 10.18632/oncotarget.6215. No abstract available.

26.

Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma.

Chiu AP, Tschida BR, Lo LH, Moriarity BS, Rowlands DK, Largaespada DA, Keng VW.

World J Gastroenterol. 2015 Nov 14;21(42):12157-70. doi: 10.3748/wjg.v21.i42.12157. Review.

27.

RNA sequencing of Sleeping Beauty transposon-induced tumors detects transposon-RNA fusions in forward genetic cancer screens.

Temiz NA, Moriarity BS, Wolf NK, Riordan JD, Dupuy AJ, Largaespada DA, Sarver AL.

Genome Res. 2016 Jan;26(1):119-29. doi: 10.1101/gr.188649.114. Epub 2015 Nov 9.

28.

A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma.

Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J, Machiela MJ, Pankratz N, Panagiotou OA, Largaespada D, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, de Toledo SR, Petrilli AS, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Andrulis IL, Wunder JS, Gokgoz N, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF, Halai D, Ballinger ML, Thomas DM, Davis S, Barkauskas DA, Marina N, Helman L, Otto GM, Becklin KL, Wolf NK, Weg MT, Tucker M, Wacholder S, Fraumeni JF Jr, Caporaso NE, Boland JF, Hicks BD, Vogt A, Burdett L, Yeager M, Hoover RN, Chanock SJ, Savage SA.

Cancer Discov. 2015 Sep;5(9):920-31. doi: 10.1158/2159-8290.CD-15-0125. Epub 2015 Jun 17.

29.

Sleeping Beauty transposon insertional mutagenesis based mouse models for cancer gene discovery.

Moriarity BS, Largaespada DA.

Curr Opin Genet Dev. 2015 Feb;30:66-72. doi: 10.1016/j.gde.2015.04.007. Epub 2015 Jun 4. Review.

30.

A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis.

Moriarity BS, Otto GM, Rahrmann EP, Rathe SK, Wolf NK, Weg MT, Manlove LA, LaRue RS, Temiz NA, Molyneux SD, Choi K, Holly KJ, Sarver AL, Scott MC, Forster CL, Modiano JF, Khanna C, Hewitt SM, Khokha R, Yang Y, Gorlick R, Dyer MA, Largaespada DA.

Nat Genet. 2015 Jun;47(6):615-24. doi: 10.1038/ng.3293. Epub 2015 May 11.

31.

Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia.

Rathe SK, Moriarity BS, Stoltenberg CB, Kurata M, Aumann NK, Rahrmann EP, Bailey NJ, Melrose EG, Beckmann DA, Liska CR, Largaespada DA.

Sci Rep. 2014 Aug 13;4:6048. doi: 10.1038/srep06048.

32.

PVT1 dependence in cancer with MYC copy-number increase.

Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadnell TC, Essig J, Otto GM, O'Sullivan MG, Largaespada DA, Schwertfeger KL, Marahrens Y, Kawakami Y, Bagchi A.

Nature. 2014 Aug 7;512(7512):82-6. doi: 10.1038/nature13311. Epub 2014 Jun 22.

33.

HomeRun Vector Assembly System: a flexible and standardized cloning system for assembly of multi-modular DNA constructs.

Li MV, Shukla D, Rhodes BH, Lall A, Shu J, Moriarity BS, Largaespada DA.

PLoS One. 2014 Jun 24;9(6):e100948. doi: 10.1371/journal.pone.0100948. eCollection 2014.

34.

Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.

Rahrmann EP, Moriarity BS, Otto GM, Watson AL, Choi K, Collins MH, Wallace M, Webber BR, Forster CL, Rizzardi AE, Schmechel SC, Ratner N, Largaespada DA.

Am J Pathol. 2014 Jul;184(7):2082-98. doi: 10.1016/j.ajpath.2014.04.006. Epub 2014 May 13.

35.

Simple and efficient methods for enrichment and isolation of endonuclease modified cells.

Moriarity BS, Rahrmann EP, Beckmann DA, Conboy CB, Watson AL, Carlson DF, Olson ER, Hyland KA, Fahrenkrug SC, McIvor RS, Largaespada DA.

PLoS One. 2014 May 5;9(5):e96114. doi: 10.1371/journal.pone.0096114. eCollection 2014.

36.

Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.

Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity BS, Beckmann DA, Wolf NK, Sarver A, Collins MH, Moertel CL, Wallace MR, Gel B, Serra E, Ratner N, Largaespada DA.

Nat Genet. 2013 Jul;45(7):756-66. doi: 10.1038/ng.2641. Epub 2013 May 19.

37.

Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.

Watson AL, Rahrmann EP, Moriarity BS, Choi K, Conboy CB, Greeley AD, Halfond AL, Anderson LK, Wahl BR, Keng VW, Rizzardi AE, Forster CL, Collins MH, Sarver AL, Wallace MR, Schmechel SC, Ratner N, Largaespada DA.

Cancer Discov. 2013 Jun;3(6):674-89. doi: 10.1158/2159-8290.CD-13-0081. Epub 2013 Mar 27.

38.

Modular assembly of transposon integratable multigene vectors using RecWay assembly.

Moriarity BS, Rahrmann EP, Keng VW, Manlove LS, Beckmann DA, Wolf NK, Khurshid T, Bell JB, Largaespada DA.

Nucleic Acids Res. 2013 Apr;41(8):e92. doi: 10.1093/nar/gkt115. Epub 2013 Feb 26.

39.

Conditional Inactivation of Pten with EGFR Overexpression in Schwann Cells Models Sporadic MPNST.

Keng VW, Watson AL, Rahrmann EP, Li H, Tschida BR, Moriarity BS, Choi K, Rizvi TA, Collins MH, Wallace MR, Ratner N, Largaespada DA.

Sarcoma. 2012;2012:620834. doi: 10.1155/2012/620834. Epub 2012 Dec 18.

40.

Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

Keng VW, Sia D, Sarver AL, Tschida BR, Fan D, Alsinet C, Solé M, Lee WL, Kuka TP, Moriarity BS, Villanueva A, Dupuy AJ, Riordan JD, Bell JB, Silverstein KA, Llovet JM, Largaespada DA.

Hepatology. 2013 Jan;57(1):120-30. doi: 10.1002/hep.26004. Epub 2012 Oct 19.

41.

Efficient non-viral integration and stable gene expression in multipotent adult progenitor cells.

Wilber A, Ulloa Montoya F, Hammer L, Moriarity BS, Geurts AM, Largaespada DA, Verfaillie CM, McIvor RS, Lakshmipathy U.

Stem Cells Int. 2011;2011:717069. doi: 10.4061/2011/717069. Epub 2011 Oct 2.

Supplemental Content

Loading ...
Support Center